Correlation Between ZyVersa Therapeutics and Unicycive Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both ZyVersa Therapeutics and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ZyVersa Therapeutics and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ZyVersa Therapeutics and Unicycive Therapeutics, you can compare the effects of market volatilities on ZyVersa Therapeutics and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ZyVersa Therapeutics with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of ZyVersa Therapeutics and Unicycive Therapeutics.

Diversification Opportunities for ZyVersa Therapeutics and Unicycive Therapeutics

-0.78
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between ZyVersa and Unicycive is -0.78. Overlapping area represents the amount of risk that can be diversified away by holding ZyVersa Therapeutics and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and ZyVersa Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ZyVersa Therapeutics are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of ZyVersa Therapeutics i.e., ZyVersa Therapeutics and Unicycive Therapeutics go up and down completely randomly.

Pair Corralation between ZyVersa Therapeutics and Unicycive Therapeutics

Given the investment horizon of 90 days ZyVersa Therapeutics is expected to under-perform the Unicycive Therapeutics. In addition to that, ZyVersa Therapeutics is 2.27 times more volatile than Unicycive Therapeutics. It trades about -0.16 of its total potential returns per unit of risk. Unicycive Therapeutics is currently generating about 0.11 per unit of volatility. If you would invest  50.00  in Unicycive Therapeutics on August 28, 2024 and sell it today you would earn a total of  5.00  from holding Unicycive Therapeutics or generate 10.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

ZyVersa Therapeutics  vs.  Unicycive Therapeutics

 Performance 
       Timeline  
ZyVersa Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Unicycive Therapeutics 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

ZyVersa Therapeutics and Unicycive Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with ZyVersa Therapeutics and Unicycive Therapeutics

The main advantage of trading using opposite ZyVersa Therapeutics and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ZyVersa Therapeutics position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.
The idea behind ZyVersa Therapeutics and Unicycive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance